American Urological Association Annual Meeting | Conference

Dr Dhanji on the Effect of Hypertension on Survival Outcomes in Upper Tract Urothelial Carcinoma

May 2nd 2023

Sohail Dhanji, MD, discusses the effect of preoperative hypertension on survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, and the importance of hypertension control in this population.

Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

May 2nd 2023

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

89Zr-DFO-girentuximab May Improve Identification, Risk Stratification of Renal Tumors

May 2nd 2023

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

May 2nd 2023

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBC

May 1st 2023

Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Dr Saad on PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC

May 1st 2023

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

May 1st 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

May 1st 2023

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery

May 1st 2023

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Sintilimab Plus Axitinib Has Clinical Efficacy in Advanced FH-Deficient RCC

April 30th 2023

Treatment with sintilimab in combination with axitinib resulted in tumor shrinkage with tolerable adverse effects in patients with advanced fumarate hydratase–deficient renal cell carcinoma.

Complications Following Partial Nephrectomy Associated With Particular Comorbidities in RCC

April 30th 2023

Specific comorbidities were linked with complications following partial nephrectomy, compared with radical nephrectomy, in patients with T1b to T2 renal cell carcinoma.

Hypertension Linked With Worse Outcomes for Patients With Upper Tract Urothelial Cancer Undergoing Nephroureterectomy

April 30th 2023

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.

High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy

April 30th 2023

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC

April 29th 2023

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer

April 29th 2023

Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

April 29th 2023

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC

April 29th 2023

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC

April 29th 2023

A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC

April 29th 2023

A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.

Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC

April 29th 2023

Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.